This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adinoff, A. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Adinoff, A. D.

PEDIATRICS Vol. 104 No. 2 Supplement August 1999, pp. 384

beta -Adrenergic Agonist Therapy
Effects of Treatment with Formoterol on Bronchoprotection AgainstMethacholine

Lipworth B, Tan S, Devlin M, Aiken T, Baker R, Hendrick D Am J Med. 1998; 104:431-438 [Medline]

The first 20% of the full text of this article appears below.

Purpose of the Study In addition to their bronchodilatory effects, beta 2-agonists protect against bronchoconstriction, such as that caused by methacholine challenge. However, tachyphylaxis to this beneficial effect develops after chronic use of beta 2-agonists. They studied whether the frequency or dose of treatment with a long-acting beta 2-agonist (formoterol) effects the degree of bronchoprotection afforded against methacholine challenge and to compare this with the effects of a short-acting beta 2-agonist (terbutaline).

Study Population and Methods In a randomized, parallel group, double-blind study at two . . . [Full Text of this Article]